Smoking Addiction
Overview
In smoking addiction, people experience an uncontrollable
dependence on cigarettes, which on stopping will cause severe mental, emotional
or physical reactions. People addicted to smoking develop tolerance to
nicotine. Nicotine acts on acetylcholine receptors causing the body to react to
nicotine at these receptors in the same manner as it responds to acetylcholine.
This leads to alterations in the activity and physiological functions of many
brain systems. This causes structural and functional changes in the brains of
smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body
get disturbed, leading to a condition called withdrawal syndrome. The body
usually takes time to function in the absence of nicotine. The effects of
smoking withdrawal stem from the lack of nicotine that can be overcome by
nicotine replacement therapies such as the use of nicotine patch or nicotine
chewing gum.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1418409-smoking-addiction-pipeline-review-h1-2017
Smoking Addiction Industry Major
Outlook
The Pharmaceutical and Healthcare latest pipeline guide
Smoking Addiction - Pipeline Review, H1 2017, provides comprehensive
information on the therapeutics under development for Smoking Addiction
(Central Nervous System), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and
press releases.
The Smoking Addiction (Central Nervous System) pipeline guide
also reviews of key players involved in therapeutic development for Smoking Addiction
and features dormant and discontinued projects. The guide covers therapeutics
under Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery
and Unknown stages are 1, 5, 8, 6, 3 and 1 respectively. Similarly, the
Universities portfolio in Preclinical and Discovery stages comprises 2 and 1
molecules, respectively.
Smoking Addiction (Central Nervous System) pipeline guide
helps in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured on a
real time basis.
Smoking Addiction -
Competitive Analysis
Key players are making innovative
developments in Smoking Addiction industry. The same will help in improving the market
performance. Heavy investments are made by major players in the R&D sector
Scope
- The pipeline guide provides a snapshot of the global
therapeutic landscape of Smoking Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)
- The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)
.Continued
For Detailed Reading Please visit @
https://www.wiseguyreports.com/reports/1418409-smoking-addiction-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt.
Ltd. and offers premium progressive statistical surveying, market research
reports, analysis & forecast data for industries and governments around the
globe. Wise Guy Reports understand how essential statistical surveying
information is for your organization or association. Therefore, we have
associated with the top publishers and research firms all specialized in
specific domains, ensuring you will receive the most reliable and up to date
research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment